



# Povidone-Iodine (PVI) has a profound effect on in vitro osteoblast proliferation and metabolic function and inhibits their ability to mineralise and form bone

Newton Ede, Matthew P.; Philp, Ashleigh M.; Richardson, Stephen M.; Saeed, Mohammed; Jones, Simon

DOI:

[10.1097/BRS.0000000000001332](https://doi.org/10.1097/BRS.0000000000001332)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Newton Ede, MP, Philp, AM, Richardson, SM, Saeed, M & Jones, S 2016, 'Povidone-Iodine (PVI) has a profound effect on in vitro osteoblast proliferation and metabolic function and inhibits their ability to mineralise and form bone', *Spine*, vol. 41, no. 9, pp. 729-734. <https://doi.org/10.1097/BRS.0000000000001332>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

This document constitutes the accepted version of the article detailed above. The final version of record is published as: Newton, Ede MP, et al. "Povidone-Iodine (PVI) has a Profound Effect on in vitro Osteoblast Proliferation and Metabolic Function and Inhibits Their Ability to Mineralise and form Bone." *Spine* (2015) and is available at: <http://dx.doi.org/10.1097/BRS.0000000000001332>

Checked Feb 2016

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 01. Mar. 2020

**DOI :** 10.1097/BRS.0000000000001332

**Povidone-Iodine (PVI) has a profound effect on in vitro osteoblast proliferation and metabolic function and inhibits their ability to mineralise and form bone**

Matthew P. Newton Ede<sup>1</sup>\*M.B.B.S., Ashleigh M. Philp, MSc<sup>2</sup>\*, Andrew Philp<sup>2</sup>PhD, Stephen M. Richardson<sup>3</sup>PhD, Saeed Mohammad<sup>4</sup>MD, Simon W. Jones<sup>2</sup>PhD

\*Denotes joint first authorship.

<sup>1</sup> The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP

<sup>2</sup> MRC-ARUK Centre for Musculoskeletal Ageing Research, Medical School, Queen Elizabeth Hospital, University of Birmingham, B15 2WB.

<sup>3</sup> Centre for Tissue Injury and Repair, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, The University of Manchester, Stopford Building, Oxford Rd, Manchester, M13 9PT

<sup>4</sup> Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD

\* Corresponding author

**Please address all correspondence to**

Simon W. Jones

MRC-ARUK Centre for Musculoskeletal Ageing Research,  
Medical School, Queen Elizabeth Hospital,  
University of Birmingham,  
B15 2WB.

Email: S.W.jones@bham.ac.uk

+44 121 371 3224

The device(s)/drug(s) that is/are the subject of this manuscript is/are not FDA-approved for this indication and is/are not commercially available in the United States.

The British Scoliosis Research Foundation (BSRF) reference R114624 funds were received in support of this work.

No relevant financial activities outside the submitted work.

ACCEPTED

## Structured Abstract

**Study Design.** A study examining the clinical protocol of scoliosis wound irrigation, demonstrating Povidone-Iodine's (PVI) effect on human osteoblast cells. Primary and immortal cell line osteoblasts were treated with 0.35% PVI for 3 minutes, and analyzed for proliferation rate, oxidative capacity and mineralisation.

**Objective.** To model spinal wound irrigation with dilute PVI *in vitro*, in order to investigate the effect of PVI on osteoblast proliferation, metabolism and bone mineralisation.

**Summary of Background Data.** Previously PVI irrigation has been proposed as a safe and effective practice to avoid bacterial growth following spinal surgery. However, recent evidence in multiple cell types suggests that PVI has a deleterious effect on cellular viability and cellular function.

**Methods.** Primary and immortal human osteoblast cells were exposed to either PBS control or with 0.35% PVI for 3 min. Cellular proliferation was measured over the duration of 7 days by MTS assay. Oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and proton production rate (PPR) were analysed using a Seahorse XFe24 Bioanalyzer. Protein expression of the electron transport chain subunits CII-SDHB, CIII-UQRCR2 and CV-ATP5A were measured via Western blotting. Mineralised bone nodules were stained with alizarin red.

**Results.** Expressed as a percentage of normal osteoblast proliferation, osteoblasts exposed to 0.35% PVI exhibited a significant 24% decrease in proliferation after 24 h. This was a sustained response, resulting in a 72% decline in cellular proliferation at 1 week. There was a significant reduction in OCR, ECAR, and PPR ( $p < 0.05$ ), in osteoblasts that had been exposed

to 0.35% PVI for 3 min, coupled with a marked reduction in the protein expression of CII-SDHB. Osteoblasts exposed to 0.35% PVI exhibited reduced bone nodule mineralisation compared to control PBS exposed osteoblasts ( $p<0.01$ ).

**Conclusion.** PVI has a rapid and detrimental effect on human osteoblast cellular proliferation, metabolic function, and bone nodule mineralisation.

**Key Words:** Povidone-Iodine, PVI, Osteoblasts, wound irrigation, Spinal Surgery, Bone Mineralization, Cellular Metabolism, Cell Viability, Cell Proliferation

**Level of Evidence:** N/A

## Introduction

Surgical wound infection is a serious complication following spinal surgery. Infection rates in spinal surgery vary hugely and are dependent on a plethora of factors including patient co-morbidities and type of surgery being performed. In particular deformity correction procedures, with long wounds, long operating times and medical co-morbidities; infection rates can be as high as 19%. Surgical site infections can progress to deep infection, incur multiple operations with increased healthcare costs and impaired patient outcomes (1-6).

To reduce the risk of wound infections, many spinal surgeons are using intra-operative antimicrobial wound irrigates (7). One such irrigate which has been advocated and utilised is dilute Povidone-Iodine (PVI) (8). However, there is a paucity of evidence supporting this off-label practice. Two clinical papers have previously described this as a safe and effective practice (8, 9) but there is evidence that PVI has a deleterious effect on cellular viability and cellular function. Studies across multiple cells types and tissues, including fibroblasts, keratinocytes, chondrocyte, immune cells and synovial tissue have now demonstrated that PVI has cytotoxic effects (10-13).

The PVI wound irrigation technique, as described by Chang et al. (9), involves complete immersion of the wound for 3 minutes with a preparation of 0.35% of PVI (diluted from commercially available 10% PVI “Videne”), followed by copious irrigation with normal saline, prior to decortication and wound closure.

Two laboratory studies (one human, one animal) describe the effects of PVI on osteoblasts. Whilst results were heterogeneous, all described a toxic effect of PVI on the osteoblast (14, 15).

From a spinal surgery perspective, there are no studies which have examined whether PVI at clinically advocated concentrations has deleterious effects on human osteoblast viability and function. Addressing this is imperative since osteoblast proliferative and metabolic activity, together with their ability to form bone and mineralise, is essential for the establishment of solid fusion post-surgery.

The aim of this study was to model the clinical protocol *in vitro*, in order to investigate the effect of dilute PVI washout on osteoblast proliferation, metabolic function and osteoblast bone nodule formation and mineralisation.

## **METHODS**

### **3.1 Cell culture**

Primary human osteoblast cells were cultured in differentiation media (10% fetal calf serum (FCS), penicillin (100 units/ml), streptomycin (100µg/ml), L-glutamine (2mM), non-essential amino acids (1%, Invitrogen) and Amphotericin B (2.5 µg/ml), β-glycerophosphate (2mM), Ascorbic acid (50µg/ml) and Dexamethasone (10nM)) entirely. The human osteoblast cell line hFOB 1.19 (ATCC® CRL-11372™) (ATCC, England, UK) was cultured in growth media (1:1 mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium, with 2.5 mM L-glutamine (without phenol red), 10% fetal bovine serum (FBS), and 0.3mg/ml G418 prior to differentiation media.

### **3.2 Preparation of primary human osteoblasts**

Ethical approval was granted by the United Kingdom (UK) National Research Ethics Service (National Health Authority, reference NRES 14-ES-1044), and institutionally approved and sponsored by the University of Birmingham as required under the UK Research Governance

Framework. Study participants were provided in advance with a participant information sheet, and a participant consent form. Following patient's written consent, the femoral head was collected from a female patient (aged 62 years) undergoing total joint replacement surgery for hip osteoarthritis. The articular cartilage was removed from the femoral head and the subchondral bone cut into small chips. The bone chips were then washed thoroughly in serum-free primary osteoblast media to remove any excess blood, connective or adipose tissue and then incubated in differentiation media in a culture flask at 37°C (5% CO<sub>2</sub>). Differentiation media was replaced with fresh media 2x per week, and the bone chips removed upon the appearance of osteoblast cells.

### **3.3 Osteoblast proliferation assay**

Primary human osteoblasts and the human osteoblast cell line (hFOB 1.19) were plated at  $6 \times 10^3$  cells per well in a 96 well plate. At confluency, the cells were incubated with either PBS control or with 0.35% PVI (diluted in PBS) for 3 minutes at room temperature. The wells were then aspirated, washed 5x with PBS and then placed back into osteoblast growth media. After 24, 48, 120, 144 and 168 h at 33°C, an MTS (Cell Titer Aqueous One Solution Cell Proliferation Assay, Promega) assay was performed as per manufacturer's instructions as a measure of osteoblast proliferation.

### **3.4 Osteoblast metabolic function**

Human osteoblast cells (hFOB 1.19) were plated at  $6 \times 10^3$  cells per well in an XF<sup>®</sup> 24 Cell Culture Microplate (Seahorse Bioscience, USA). At confluency, the cells were stimulated with 0.35% PVI diluted in PBS or with PBS control for 3min, thoroughly washed as described previously and placed back into growth media. After 24 h at 33°C, XF Assay



medium (XF base medium with 2mM GlutaMAX™) was then added to the plate and incubated at 33°C for 1 h.

Using a XF<sup>e</sup> Extracellular Flux Analyzer (Seahorse Bioscience, USA) the oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and proton production rate (PPR) of each well were measured simultaneously, in order to comprehensively profile the metabolic function of the osteoblasts.

### **3.5 Expression analysis of osteoblast mitochondrial oxidative phosphorylation components**

Human osteoblast cells (hFOB 1.19) cells were seeded at  $6 \times 10^4$  cells per well in a 24-well plate. Cells were stimulated with 0.35% dilute PVI or PBS control for 3min, and then washed in PBS as previously described before being cultured in growth media for 24 h (37°C, 5% CO<sub>2</sub>). Following 24 h, cells were washed in PBS and lysed in 1xLaemmli Sample Buffer (2%SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.002% Bromophenol Blue, 0.0625M Tris HCL). Equal amounts of total protein lysates were then applied to 12% SDS PAGE electrophoresis and blotted onto polyvinylidene difluoride (PVDF) membrane at 150V for 1 h. Blots were immunoprobed with an optimised antibody cocktail which contains antibodies to detect key components of mitochondrial oxidative phosphorylation, namely CII-SDHB 30kDa (ab14714), CIII-UQCRC2 (ab14745) and CV-ATP5A (ab14748). Blots were developed using ECL™ Prime Western Blotting Detection Reagent Kit (GE Healthcare, UK) on the ChemiDoc™ Imaging MP System (BIO-RAD, USA).

### **3.7 Osteoblast bone nodule formation and mineralization assay**

Human osteoblast cells (hFOB 1.19) were seeded at  $6 \times 10^4$  cells per well in a 24 well plate and treated with or without 0.35% PVI for 3 min as described previously, before being cultured in differentiation media. After 14 days, cells were stained with alizarin red solution in order to quantify the degree of mineralisation following the formation of bone nodules. Briefly, cells were incubated in alizarin red staining solution (0.5% Alizarin Red (Sigma-Aldrich, UK) in 1% ammonia solution at pH 4.5) for 10min at room temperature and washed with PBS to remove excess stain. Cells were then incubated in 10% cetyl pyridinium chloride (Sigma-Aldrich, UK) for 10 min at room temperature. The supernatant was collected from each well and diluted 1:10 with the 10% cetyl pyridinium chloride and read at OD<sub>550nm</sub> on a SpectraMAX Microplate Reader (Molecular Devices, USA).

### **3.8 Statistical Analysis**

All statistical analyses were carried out using Prism5 (GraphPad Software Inc. California, USA). Unless otherwise stated, all data within figures represents Mean  $\pm$  SEM. MTS assay results were assessed by a one-way analysis of variance (ANOVA) with a Tukey Post Hoc. OCR, ECAR and PPR, and alizarin red analysis was compared using a Students un-paired t-test.

## **RESULTS**

### **3.1 Acute exposure to PVI markedly reduces osteoblast proliferation.**

Acute 3 min exposure of primary human osteoblasts to PVI at the clinical concentration of 0.35% significantly decreased cellular proliferation at 48, 120 and 168 h post-exposure (Figure 1A). Expressed as a percentage of normal osteoblast proliferation (PBS control), osteoblasts exposed to 0.35% PVI exhibited a  $24 \pm 3.7\%$  decrease in proliferation after 24 h

(Figure 1B). This was a sustained response, which resulted in a  $72\% \pm 2.3\%$  decline in cellular proliferation at 1 week. The significant effect of PVI on cellular proliferation was also confirmed in the human osteoblast cell line (hFOB 1.19) (Figure 1C & 1D), with a  $26 \pm 3\%$  after 24 h, and a  $42\% \pm 7\%$  decline in proliferation relative to control after 6 days post-exposure.

### **3.2 Acute exposure of osteoblasts to dilute PVI ablates osteoblast basal metabolic function.**

Assessment of metabolic functional activity of osteoblasts (hFOB.1.19) 24 h post-exposure to 0.35% PVI or PBS control showed a significant reduction in OCR ( $0.32 \pm 0.13$  vs  $-0.05 \pm 0.12$  pmol/min/ $\mu$ g), ECAR ( $0.10 \pm 0.07$  vs  $0.01 \pm 0.02$  mpH/min/ $\mu$ g) and PPR ( $87.64 \pm 18.78$  vs  $3.33 \pm 7.24$  pmol/min/ $\mu$ g) (Figure 2A-C) in osteoblasts that had been exposed to 0.35% PVI for 3 min.

### **3.3 Acute exposure of human osteoblasts to PVI markedly reduces CIII-SDHB protein expression, a key component of oxidative phosphorylation.**

To identify if the effect of 0.35% PVI on osteoblast metabolic function was due to a deleterious effect on mitochondrial function we then assessed the protein expression of electron transport chain subunits (II, III and CV), involved in mitochondrial oxidative phosphorylation. Human osteoblasts exposed to 0.35% PVI for 3 min exhibited a marked reduction in protein expression of succinate dehydrogenase B (CII-SDHB), and a moderate reduction in the protein expression of cytochrome b-c1 complex subunit 2 (CIII-UQCRC2), compared to PBS control exposed osteoblasts. The protein expression of CV-ATP5A remained unchanged (Figure 2D).

### 3.4 Acute stimulation with PVI reduces osteoblast mineralization

We next determined whether the deleterious effects of 0.35% PVI on osteoblast proliferation and metabolic functional activity impacted on the ability of osteoblasts to form bone nodules and mineralise. At confluency, osteoblasts were stimulated with 0.35% PVI for 3 min, washed with PBS thoroughly and allowed to proliferate and differentiate for a further 2 weeks in differentiation media. Alizarin red stained mineralisation was quantified and showed that osteoblasts exposed to 0.35% PVI exhibited significantly reduced bone nodule mineralisation ( $0.28 \pm 0.05$ ), compared to control PBS exposed osteoblasts ( $0.37 \pm 0.06$ ) (Figure 3).

## Discussion

PVI is advocated for wound irrigation following spinal surgery (8, 9), despite recent reports of its cytotoxicity in multiple cell types (10-13). Our *in vitro* study demonstrates that dilute PVI has fundamental deleterious effects on human osteoblast cells and their innate ability to mineralise.

Utilising primary human osteoblasts, we have demonstrated that acute exposure of osteoblasts to PVI for only 3 min, followed by thorough washing, is sufficient to profoundly inhibit cellular proliferation. Dilute PVI was found to significantly inhibit proliferation within the first 24 h following the 3 min exposure to PVI. However, perhaps of greater concern, our data also reveals that the negative effects on proliferation are fully sustained over a time-course of 7 days, resulting in a 72% inhibition of proliferation at this time point. This demonstrates that once exposed to dilute PVI the osteoblast cells do not recover their proliferative activity. Critically, we have also demonstrated that exposure to dilute PVI inhibits the innate functional ability of osteoblasts to form mineralised bone nodules.

Our data suggests that exposure to dilute PVI inhibits human osteoblast proliferation and mineralisation by preventing normal osteoblast metabolic function, since both basal oxygen consumption rate (a measure of aerobic mitochondrial respiration; (16)) and extracellular acidification rate and proton production rate (a measure of glycolytic metabolism; (16)) were ablated within 24 h post-exposure to 3 min of dilute PVI.

With regard to previous studies which have reported the effect of PVI on the osteoblast, Kaysinger (1995) found that 5% Betadine (0.5% PVI) was toxic to chicken osteoblasts (15). It is of note that the first non-toxic concentration reported by Kaysinger was 5% Betadine (0.5% PVI). From their results it is therefore not possible to ascertain where between 0.05% and 0.5% the toxic effects of PVI are manifested (15). In the paper of Cheng et al. (8) the concentration of 0.5% PVI appears to have been interpreted as the lowest toxic concentration and hence guided their choice of 0.35% PVI for irrigation. We would argue that this was a fundamental misinterpretation of the report of Kaysinger et al. We have now confirmed that 0.35% PVI is indeed toxic to human osteoblasts.

Cabral et al (2007) assessed PVI exposure in human alveolar bone. They found 10% and 5% PVI resulted in immediate cell death. 1% PVI resulted in rounding up and cellular detachment (implied cell death), and that cellular proliferation was reduced at concentrations of 0.5% PVI and higher. Cabral also reported a significant reduction in Alkaline Phosphatase (AP) production at 0.05% and 0.2% PVI (14), indicative of reduced mineralisation activity. Our findings are in agreement with this, since we also found that PVI reduced osteoblast proliferation and have demonstrated a significant reduction in the production of mineralised bone (as measured by Alizarin red staining) with 0.35% PVI.

Infection rates in spinal surgery vary widely. For example, infection rate following anterior cervical surgery is low, at around 0.1%, but infection rates can be up to 19% in spinal deformity surgery (5, 17). Critically, the results of deep infection can be devastating and occasionally fatal in patient groups with multiple co-morbidities. Clearly therefore, efforts must be taken to reduce spinal infection. A very informative Best Practice Guideline in 2013 made a number of recommendations for the “high risk” spinal surgical patients. These included pre-operative washing with chlorhexidine, nutritional assessment, broad spectrum antibiotics and topical vancomycin powder. It is noteworthy that PVI irrigation was not among the recommendations (18).

In 2005 and 2006 two reports from the same centre described the utilization of 0.35% PVI lavage in spinal surgery (8, 9), and reported a clinically significant reduction in infection rates from 2.9% without PVI lavage, to 0.5% with PVI lavage. Clearly this is a commendable reduction in infection rates apparently attributable to the PVI lavage. However, the goal of many spinal surgeries is the establishment of solid bony fusion (union). Therefore, the potential negative effect of a given irrigate on bone union must be considered alongside any positive benefit on spinal infection rates.

Measurement of union (and non-union) are difficult to comprehensively determine using Computed Tomography (CT) (Carreon et al. 2008). The only reliable method is surgical exploration. In lumbar fusion surgery non-union rates are reported to be 10-20%. In fusions of 4-levels or more, and in particular in adult degenerative scoliosis the rate of non-union can be as high as 20- 60% (9, 19-21).

Our study identifies a potential pathway for impaired bony union following PVI lavage in the clinical setting. The two reports from Cheng et al. (8) clearly state that on radiographic analysis there was no adverse effect on fusion rates. However, it is noteworthy that the patients in these studies were overwhelmingly 2-level or fewer low-back fusions. These particular patients have a fairly predictable union rate of around 80-90%. It is possible therefore that the deleterious effect of PVI on the human osteoblast may have a greater clinical impact on longer fusions with higher inherent risks of non-union. Additionally Chang et al. (9) used plain X-ray for evaluation of bony fusion. This is not a reliable method for assessing bony fusion, with only 68% accuracy in lumbar spine fusions (22).

Outside the scope of this report, but of importance to the surgeon considering using PVI for irrigation of surgical wounds are descriptions of systemic complications following iodine lavage. These include: significant systemic iodine absorption, acute thyroid dysfunction, cardiovascular collapse, renal failure and death. Whilst these are not immediately relevant to bone healing, it does suggest that iodine lavage is not a universally benign phenomenon (23-27).

There are limitations to our study. It is not possible to replicate *in vitro* the entire biological system involved in bone healing. We cannot replicate or ascertain what the effect would be on the pluripotent stem cells that subsequently migrate to the site of bony healing after irrigation. We have only assessed the effect on one cell type (the osteoblast), we do not know what the effect of 0.35% PVI would be on other cell types involved in bone healing such as fibroblasts, osteoclasts and platelets. We also accept that although our primary osteoblasts were human, they were not isolated from spinal bone. It is therefore conceivable that osteoblasts within spinal bone could behave differently to osteoblasts from the appendicular

skeleton. It is reassuring however that our results are similar to those described by Kaysinger from chicken embryonic tibiae (15).

In summary, we have demonstrated a clear deleterious effect of PVI to osteoblast proliferation and function and mineralisation. We suggest the advocated antimicrobial gains may be offset by the potential for impaired bone healing, particularly in long fusion procedures with higher non-union rates, where there is no clinical outcome data relating to PVI irrigation.

## Abbreviations

<b>PVI</b>	Povidone-Iodine
<b>PBS</b>	Phosphate buffered saline
<b>MTS</b>	3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
<b>CII-SDHB</b>	Succinate Dehydrogenase B
<b>CIII-UQCRC2</b>	ubiquinol-cytochrome c reductase core protein II
<b>CV-ATP5A</b>	ATP synthase



## References

1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. *Expert review of pharmacoeconomics & outcomes research*. 2009;9(5):417-22.
2. Dohmen PM. Economic Burden of Surgical Site Infections in Cardiac Surgery. *J Med Microb Diagn*. 2013;2(3).
3. Mackenzie WG, Matsumoto H, Williams BA, Corona J, Lee C, Cody SR, et al. Surgical site infection following spinal instrumentation for scoliosis: a multicenter analysis of rates, risk factors, and pathogens. *The Journal of bone and joint surgery American volume*. 2013;95(9):800-6, S1-2.
4. Reames DL, Smith JS, Fu KM, Polly DW, Jr., Ames CP, Berven SH, et al. Complications in the surgical treatment of 19,360 cases of pediatric scoliosis: a review of the Scoliosis Research Society Morbidity and Mortality database. *Spine (Phila Pa 1976)*. 2011;36(18):1484-91.
5. Duckworth AD, Mitchell MJ, Tsirikos AI. Incidence and risk factors for post-operative complications after scoliosis surgery in patients with Duchenne muscular dystrophy : a comparison with other neuromuscular conditions. *Bone Joint J*. 2014;96-B(7):943-9.
6. Smith JS, Shaffrey CI, Sansur CA, Berven SH, Fu KM, Broadstone PA, et al. Rates of infection after spine surgery based on 108,419 procedures: a report from the Scoliosis Research Society Morbidity and Mortality Committee. *Spine (Phila Pa 1976)*. 2011;36(7):556-63.
7. Glotzbecker BE, Yolin-Raley DS, DeAngelo DJ, Stone RM, Soiffer RJ, Alyea EP, 3rd. Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. *Journal of oncology practice / American Society of Clinical Oncology*. 2013;9(5):e228-33.
8. Cheng MT, Chang MC, Wang ST, Yu WK, Liu CL, Chen TH. Efficacy of dilute betadine solution irrigation in the prevention of postoperative infection of spinal surgery. *Spine (Phila Pa 1976)*. 2005;30(15):1689-93.

9. Chang FY, Chang MC, Wang ST, Yu WK, Liu CL, Chen TH. Can povidone-iodine solution be used safely in a spinal surgery? *Eur Spine J*. 2006;15(6):1005-14.
10. Balin AK, Pratt L. Dilute povidone-iodine solutions inhibit human skin fibroblast growth. *Dermatologic surgery* : official publication for American Society for Dermatologic Surgery [et al]. 2002;28(3):210-4.
11. Cooper ML, Laxer JA, Hansbrough JF. The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. *The Journal of trauma*. 1991;31(6):775-82; discussion 82-4.
12. Van den Broek PJ, Buys LF, Van Furth R. Interaction of povidone-iodine compounds, phagocytic cells, and microorganisms. *Antimicrobial agents and chemotherapy*. 1982;22(4):593-7.
13. von Keudell A, Canseco JA, Gomoll AH. Deleterious Effects of Diluted Povidone-Iodine on Articular Cartilage. *J Arthroplasty*. 2013;28(6):918-21.
14. Cabral CT, Fernandes MH. In vitro comparison of chlorhexidine and povidone-iodine on the long-term proliferation and functional activity of human alveolar bone cells. *Clin Oral Investig*. 2007;11(2):155-64.
15. Kaysinger KK, Nicholson NC, Ramp WK, Kellam JF. Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts. *J Orthop Trauma*. 1995;9(4):303-11.
16. Pike Winer LS, Wu M. Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate. *PloS one*. 2014;9(10):e109916.
17. Bohl DD, Webb ML, Lukasiewicz AM, Samuel AM, Basques BA, Ahn J, et al. Timing of Complications Following Spinal Fusion Surgery. *Spine (Phila Pa 1976)*. 2015.
18. Vitale MG, Riedel MD, Glotzbecker MP, Matsumoto H, Roye DP, Akbarnia BA, et al. Building consensus: development of a Best Practice Guideline (BPG) for surgical site infection (SSI) prevention in high-risk pediatric spine surgery. *J Pediatr Orthop*. 2013;33(5):471-8.

19. Tsutsumimoto T, Shimogata M, Yoshimura Y, Misawa H. Union versus nonunion after posterolateral lumbar fusion: a comparison of long-term surgical outcomes in patients with degenerative lumbar spondylolisthesis. *Eur Spine J.* 2008;17(8):1107-12.
20. Koller H, Pfanz C, Meier O, Hitzl W, Mayer M, Bullmann V, et al. Factors influencing radiographic and clinical outcomes in adult scoliosis surgery: a study of 448 European patients. *Eur Spine J.* 2015.
21. Yamada K, Abe Y, Yanagibashi Y, Hyakumachi T, Satoh S. Mid- and long-term clinical outcomes of corrective fusion surgery which did not achieve sufficient pelvic incidence minus lumbar lordosis value for adult spinal deformity. *Scoliosis.* 2015;10(Suppl 2):S17.
22. Kant AP, Daum WJ, Dean SM, Uchida T. Evaluation of lumbar spine fusion. Plain radiographs versus direct surgical exploration and observation. *Spine (Phila Pa 1976).* 1995;20(21):2313-7.
23. Campistol JM, Abad C, Nogue S, Bertran A. Acute Renal-Failure in a Patient Treated by Continuous Povidone-Iodine Mediastinal Irrigation. *J Cardiovasc Surg.* 1988;29(4):410-2.
24. D'Auria J, Lipson S, Garfield JM. Fatal iodine toxicity following surgical debridement of a hip wound: case report. *J Trauma.* 1990;30(3):353-5.
25. Aronoff GR, Friedman SJ, Doedens DJ, Lavelle KJ. Increased serum iodide concentration from iodine absorption through wounds treated topically with povidone-iodine. *Am J Med Sci.* 1980;279(3):173-6.
26. Rath T, Meissl G. Induction of hyperthyroidism in burn patients treated topically with povidone-iodine. *Burns Incl Therm Inj.* 1988;14(4):320-2.
27. Kurt TL, Morgan ML, Hnilica V, Bost R, Petty CS. Fatal iatrogenic iodine toxicity in a nine-week old infant. *J Toxicol Clin Toxicol.* 1996;34(2):231-4.

Figure 1. The effect of acute exposure to dilute PVI on the proliferation of primary human osteoblasts and a human osteoblast cell line. **A.** Primary human osteoblasts stimulated with PBS and 0.35% PVI for 3 minutes prior to time dependent MTS assays.  $\circ$  = PBS control;  $\bullet$  = 0.35% PVI stimulated (\* $p$ <0.05, \*\*\* $p$ <0.001). **B.** Percentage proliferation of primary osteoblasts when compared to PBS control stimulated osteoblasts (\*\* $p$ <0.01 between 24 and 120 h, § $p$ <0.001 between 24 and 168 h, † $p$ <0.01 between 48 and 168 h). **C.** hFOB 1.19 cell proliferation as measured by MTS assay (\* $p$ <0.05, \*\*\* $p$ <0.001). **D.** Percentage proliferation of hFOB 1.19 osteoblasts when compared to PBS control stimulated osteoblasts (\* $p$ <0.05;  $n$ =3).




Figure 2. Metabolic activity of stable osteoblast culture following acute PVI stimulation. A. Oxygen consumption rate (OCR) of osteoblasts. B. Extracellular acidification rate of osteoblasts. C. Proton production rate of osteoblasts (Figure 2A-C n=4,  $*=p<0.05$ ). D. Western blot of cells stimulated with 0.35% PVI or PBS control 24 h prior to lysis and assayed for mitochondrial protein expression (n=3).




Figure 3. Osteoblast mineralization following acute PVI stimulation. Alizarin red staining of osteoblasts treated with 0.35% PVI or PBS control was quantified at OD<sub>550nm</sub> using 10% cetyl pyridinium chloride. (n=8, \*\*p<0.01).

